T E DeFor

Summary

Affiliation: University of Minnesota
Country: USA

Publications

  1. ncbi request reprint Early antithymocyte globulin therapy improves survival in patients with steroid-resistant acute graft-versus-host disease
    Margaret L Macmillan
    Department of Pediatrics, Blood and Marrow Transplant Program, University of Minnesota, Minneapolis 55455, USA
    Biol Blood Marrow Transplant 8:40-6. 2002
  2. ncbi request reprint Enhancement of the anti-tumor activity of a peripheral blood progenitor cell graft by mobilization with interleukin 2 plus granulocyte colony-stimulating factor in patients with advanced breast cancer
    L J Burns
    Department of Medicine, University of Minnesota, Minneapolis 55455, USA
    Exp Hematol 28:96-103. 2000
  3. ncbi request reprint Determinants of survival after human leucocyte antigen-matched unrelated donor bone marrow transplantation in adults
    Juliet N Barker
    The University of Minnesota Blood and Marrow Transplant Program, Minneapolis, MN 55455, USA
    Br J Haematol 118:101-7. 2002
  4. ncbi request reprint New malignancies after blood or marrow stem-cell transplantation in children and adults: incidence and risk factors
    K Scott Baker
    Department of Pediatrics, Blood and Marrow Transplant Program, University of Minnesota, Minneapolis 55455, USA
    J Clin Oncol 21:1352-8. 2003
  5. ncbi request reprint Rapid and complete donor chimerism in adult recipients of unrelated donor umbilical cord blood transplantation after reduced-intensity conditioning
    Juliet N Barker
    Divisions of Medical and Pediatric Hematology, Oncology and Transplantation, University of Minnesota Blood and Marrow Transplant Program, Minneapolis, MN, USA
    Blood 102:1915-9. 2003
  6. ncbi request reprint A randomized trial of the effect of a walking regimen on the functional status of 100 adult allogeneic donor hematopoietic cell transplant patients
    Todd E DeFor
    Blood and Marrow Transplant Program of the Department of Pediatrics, University of Minnesota, Cancer Center and School of Medicine, Minneapolis, Minnesota 55455, USA
    Biol Blood Marrow Transplant 13:948-55. 2007
  7. doi request reprint A modified comorbidity index for hematopoietic cell transplantation
    T E DeFor
    Biostatistics and Informatics Core, Masonic Cancer Center, University of Minnesota, Minneapolis, MN 55455, USA
    Bone Marrow Transplant 45:933-8. 2010
  8. ncbi request reprint Successful engraftment without radiation after fludarabine-based regimen in Fanconi anemia patients undergoing genotypically identical donor hematopoietic cell transplantation
    Poh Lin Tan
    Department of Pediatrics, Blood and Marrow Transplant Program, University of Minnesota, Minneapolis, Minnesota 55455, USA
    Pediatr Blood Cancer 46:630-6. 2006
  9. pmc Myeloablative hematopoietic cell transplantation for acute lymphoblastic leukemia: analysis of graft sources and long-term outcome
    Michael B Tomblyn
    Department of Therapeutic Radiology and Radiation Oncology, University of Minnesota, Minneapolis, MN 55455, USA
    J Clin Oncol 27:3634-41. 2009
  10. pmc Factors predicting single-unit predominance after double umbilical cord blood transplantation
    P Ramirez
    Department of Medicine, University of Minnesota, Blood and Marrow Transplant Program, Minneapolis, MN 55455, USA
    Bone Marrow Transplant 47:799-803. 2012

Detail Information

Publications58

  1. ncbi request reprint Early antithymocyte globulin therapy improves survival in patients with steroid-resistant acute graft-versus-host disease
    Margaret L Macmillan
    Department of Pediatrics, Blood and Marrow Transplant Program, University of Minnesota, Minneapolis 55455, USA
    Biol Blood Marrow Transplant 8:40-6. 2002
    ..These data suggest that treatment with ATG can be an active therapy, especially in patients with skin GVHD and early signs of steroid resistance...
  2. ncbi request reprint Enhancement of the anti-tumor activity of a peripheral blood progenitor cell graft by mobilization with interleukin 2 plus granulocyte colony-stimulating factor in patients with advanced breast cancer
    L J Burns
    Department of Medicine, University of Minnesota, Minneapolis 55455, USA
    Exp Hematol 28:96-103. 2000
    ..75 x 10(6) IU/m(2)/day. Fifteen women with stage IIIA/B or metastatic breast cancer underwent G-CSF mobilization alone and served as a control group...
  3. ncbi request reprint Determinants of survival after human leucocyte antigen-matched unrelated donor bone marrow transplantation in adults
    Juliet N Barker
    The University of Minnesota Blood and Marrow Transplant Program, Minneapolis, MN 55455, USA
    Br J Haematol 118:101-7. 2002
    ..Future efforts should focus on improving the outcome for older BMT recipients, especially those with diagnoses other than CML...
  4. ncbi request reprint New malignancies after blood or marrow stem-cell transplantation in children and adults: incidence and risk factors
    K Scott Baker
    Department of Pediatrics, Blood and Marrow Transplant Program, University of Minnesota, Minneapolis 55455, USA
    J Clin Oncol 21:1352-8. 2003
    ..To determine the incidence and risk factors for the development of new malignancies occurring after stem-cell transplantation (SCT)...
  5. ncbi request reprint Rapid and complete donor chimerism in adult recipients of unrelated donor umbilical cord blood transplantation after reduced-intensity conditioning
    Juliet N Barker
    Divisions of Medical and Pediatric Hematology, Oncology and Transplantation, University of Minnesota Blood and Marrow Transplant Program, Minneapolis, MN, USA
    Blood 102:1915-9. 2003
    ..These data demonstrate that 0-2 antigen mismatched UCB is sufficient to engraft most adults after reduced-intensity conditioning and is associated with a low incidence of severe acute GVHD...
  6. ncbi request reprint A randomized trial of the effect of a walking regimen on the functional status of 100 adult allogeneic donor hematopoietic cell transplant patients
    Todd E DeFor
    Blood and Marrow Transplant Program of the Department of Pediatrics, University of Minnesota, Cancer Center and School of Medicine, Minneapolis, Minnesota 55455, USA
    Biol Blood Marrow Transplant 13:948-55. 2007
    ..Structured exercise may have a positive impact on physical and emotional recovery following transplant therapy and may accelerate patients' return to health and function...
  7. doi request reprint A modified comorbidity index for hematopoietic cell transplantation
    T E DeFor
    Biostatistics and Informatics Core, Masonic Cancer Center, University of Minnesota, Minneapolis, MN 55455, USA
    Bone Marrow Transplant 45:933-8. 2010
    ..In conclusion, we are introducing the MCI which may have higher discriminating and predictive power for overall survival and NRM. Validation of the HCT-CI and the MCI in larger and separate cohorts of HCT recipients is still needed...
  8. ncbi request reprint Successful engraftment without radiation after fludarabine-based regimen in Fanconi anemia patients undergoing genotypically identical donor hematopoietic cell transplantation
    Poh Lin Tan
    Department of Pediatrics, Blood and Marrow Transplant Program, University of Minnesota, Minneapolis, Minnesota 55455, USA
    Pediatr Blood Cancer 46:630-6. 2006
    ..GVHD prophylaxis consisted of cyclosporine and short course methylprednisolone...
  9. pmc Myeloablative hematopoietic cell transplantation for acute lymphoblastic leukemia: analysis of graft sources and long-term outcome
    Michael B Tomblyn
    Department of Therapeutic Radiology and Radiation Oncology, University of Minnesota, Minneapolis, MN 55455, USA
    J Clin Oncol 27:3634-41. 2009
    ..Analysis of hematopoietic cell transplantation (HCT) for high-risk or recurrent acute lymphoblastic leukemia (ALL) using different donor sources is confounded by variable conditioning and supportive care...
  10. pmc Factors predicting single-unit predominance after double umbilical cord blood transplantation
    P Ramirez
    Department of Medicine, University of Minnesota, Blood and Marrow Transplant Program, Minneapolis, MN 55455, USA
    Bone Marrow Transplant 47:799-803. 2012
    ..4; P=0.05) were independent factors associated with unit predominance. Taken together, these findings suggest that immune reactivity has a role in unit predominance, and should be considered during graft selection and graft manipulation...
  11. doi request reprint Intra-BM injection to enhance engraftment after myeloablative umbilical cord blood transplantation with two partially HLA-matched units
    C G Brunstein
    University of Minnesota Blood and Marrow Transplant Program, Minneapolis, MN 55455, USA
    Bone Marrow Transplant 43:935-40. 2009
    ..Survival was 47% at 1 year. Despite safety of administration, IBMI of one of two UCB units did not shorten the time to neutrophil engraftment and offers no advantage over conventional double unit transplantation...
  12. doi request reprint Allogeneic hematopoietic cell transplantation in children with relapsed acute lymphoblastic leukemia isolated to the central nervous system
    Paul D Harker-Murray
    Pediatric Blood and Marrow Transplant Program, University of Minnesota, Minneapolis, Minnesota, USA
    Biol Blood Marrow Transplant 14:685-92. 2008
    ..These data support the use of allogeneic HCT in the treatment of children with poor prognosis isolated CNS relapse...
  13. ncbi request reprint Enhancement of the anti-tumor activity of a peripheral blood progenitor cell graft by mobilization with interleukin 2 plus granulocyte colony-stimulating factor in patients with advanced breast cancer
    L J Burns
    Department of Medicine, University of Minnesota, Minneapolis, MN 55455, USA
    Exp Hematol 28:352. 2000
    ....
  14. ncbi request reprint Equivalent outcomes in patients with chronic myelogenous leukemia after early transplantation of phenotypically matched bone marrow from related or unrelated donors
    S M Davies
    Blood and Marrow Transplant Program, University of Minnesota, Minneapolis 55455, USA
    Am J Med 110:339-46. 2001
    ....
  15. ncbi request reprint Long-term results of autologous stem cell transplantation for primary refractory or relapsed Hodgkin's lymphoma
    Navneet S Majhail
    Blood and Marrow Transplant Program, Divisions of Medical and Pediatric Hematology, Oncology and Transplantation, University of Minnesota, Minneapolis, MN 55455, USA
    Biol Blood Marrow Transplant 12:1065-72. 2006
    ..A risk-adapted approach should be followed in determining treatment options for patients with PR REF and REL HL...
  16. ncbi request reprint Comparable results of umbilical cord blood and HLA-matched sibling donor hematopoietic stem cell transplantation after reduced-intensity preparative regimen for advanced Hodgkin lymphoma
    Navneet S Majhail
    Blood and Marrow Transplant Program, Division of Medical and Pediatric Hematology, University of Minnesota, Minneapolis, 55455, USA
    Blood 107:3804-7. 2006
    ..67). Our results suggest comparable outcomes for reduced-intensity allo-SCT using UCB or MSD in adults at high risk with advanced Hodgkin lymphoma...
  17. ncbi request reprint Cytomegalovirus enteritis among hematopoietic stem cell transplant recipients
    J A van Burik
    Blood and Marrow Transplant Program, Department of Medicine, University of Minnesota, Minneapolis, USA
    Biol Blood Marrow Transplant 7:674-9. 2001
    ..Viremia was detected in two thirds of patients with CMV prior to the diagnosis of enteritis. Most treatment regimens included ganciclovir. The overall survival rate was 35% at 2 years following the onset of enteritis...
  18. ncbi request reprint Results of autologous and allogeneic hematopoietic cell transplant therapy for multiple myeloma
    M Arora
    Division of Hematology, Oncology and Transplantation, Department of Medicine, and the Blood and Marrow Transplant Program, University of Minnesota, MN 55455, USA
    Bone Marrow Transplant 35:1133-40. 2005
    ..Allogeneic HCT may be suitable in younger patients, soon after diagnosis, and in those with chemosensitive disease...
  19. doi request reprint New classification of chronic GVHD: added clarity from the consensus diagnoses
    M Arora
    Blood and Marrow Transplant Program, Division of Hematology, Oncology and Transplantation, Department of Medicine, University of Minnesota, Minneapolis, MN 55455, USA
    Bone Marrow Transplant 43:149-53. 2009
    ..1% (95% CI 68-94)); P=0.1. This analysis, undertaken in a contemporary cohort of related donor recipients, indicates that the consensus guidelines are applicable to this population of CGVHD patients...
  20. ncbi request reprint Oral busulfan pharmacokinetics and engraftment in children with Hurler syndrome and other inherited metabolic storage diseases undergoing hematopoietic cell transplantation
    P Jacobson
    Experimental and Clinical Pharmacology, College of Pharmacy, University of Minnesota, Minneapolis, MN, USA
    Bone Marrow Transplant 27:855-61. 2001
    ..In conclusion, we found no significant association between engraftment, marrow cell dose and BU exposure when combined with CY and TBI in children with IMSD...
  21. ncbi request reprint Alveolar hemorrhage following allogeneic hematopoietic cell transplantation using reduced-intensity conditioning
    N S Majhail
    Blood and Marrow Transplant Program, Division of Hematology, Oncology and Transplantation, University of Minnesota, Minneapolis, MN 55455, USA
    Bone Marrow Transplant 38:765-8. 2006
    ..Reducing the intensity of preparative regimen does not protect against post transplant alveolar hemorrhage. Alveolar hemorrhage occurring after RIC or MAC HCT has similar incidence, clinical presentation, and associated high mortality...
  22. ncbi request reprint The International Prognostic Index assessed at relapse predicts outcomes of autologous transplantation for diffuse large-cell non-Hodgkin's lymphoma in second complete or partial remission
    Rachel E Lerner
    Division of Hematology, Oncology, and Transplantation, University of Minnesota Medical School, 420 Delaware Street SE, Minneapolis, MN 55455, USA
    Biol Blood Marrow Transplant 13:486-92. 2007
    ..These results suggest that the IPI-R predicts OS and PFS following auto HSCT for patients with aggressive NHL in CR 2 or PR 2. Patients with high-risk IPI-R should be considered for novel therapeutic approaches...
  23. doi request reprint Allogeneic hematopoietic stem cell transplantation in adult acute lymphocytic leukemia: impact of donor source on survival
    Priya Kumar
    Blood and Marrow Transplant Program, Department of Medicine, University of Minnesota, Minneapolis, Minnesota, USA
    Biol Blood Marrow Transplant 14:1394-400. 2008
    ..4, 95% CI, 0.2-0.6, P < .01). When compared with URD:M, OS with UCB was better (RR 0.3, 95% CI, 0.1-0.7, P = .01), supporting the use of UCB as an alternative stem cell source for adults with ALL...
  24. ncbi request reprint Chronic graft-versus-host disease: a prospective cohort study
    Mukta Arora
    Department of Medicine, Blood and Marrow Transplant Program, University of Minnesota, Minneapolis, Minnesota, USA
    Biol Blood Marrow Transplant 9:38-45. 2003
    ..Recognition of a high-risk group should facilitate assignment of more intensified regimens. Better treatment regimens need to be identified to improve survival and limit toxicity of prolonged immunosuppression...
  25. doi request reprint Higher therapeutic CsA levels early post transplantation reduce risk of acute GVHD and improves survival
    J R Rogosheske
    University of Minnesota Blood and Marrow Transplant Program, Minneapolis, MN, USA
    Bone Marrow Transplant 49:122-5. 2014
    ..In patients who are near or even modestly above the CsA target trough level, in the absence of CsA-related toxicity, dose reduction should be cautious to avoid subtherapeutic drug levels resulting in higher risk of acute GVHD. ..
  26. ncbi request reprint Randomized clinical trial of ganciclovir vs acyclovir for prevention of cytomegalovirus antigenemia after allogeneic transplantation
    L J Burns
    Blood and Marrow Transplant Program, University of Minnesota, Minneapolis, MN 55455, USA
    Bone Marrow Transplant 30:945-51. 2002
    ....
  27. ncbi request reprint Randomized comparison of granulocyte colony-stimulating factor versus granulocyte-macrophage colony-stimulating factor plus intensive chemotherapy for peripheral blood stem cell mobilization and autologous transplantation in multiple myeloma
    Mukta Arora
    Department of Medicine, University of Minnesota, Minneapolis 55455, USA
    Biol Blood Marrow Transplant 10:395-404. 2004
    ..Two cycles of priming chemotherapy plus autologous transplantation yields survival rates similar to those in published reports, including those using tandem transplantation...
  28. doi request reprint Transplantation of ex-vivo culture-expanded parental haploidentical mesenchymal stem cells to promote engraftment in pediatric recipients of unrelated donor umbilical cord blood: results of a phase I-II clinical trial
    M L MacMillan
    Division of Pediatric Hematology, Oncology, and Blood and Marrow Transplantation, Department of Pediatrics University of Minnesota Medical School, Minneapolis, MN 55455, USA
    Bone Marrow Transplant 43:447-54. 2009
    ..This encouraging safety profile with haploidentical MSCs supports the investigation of unrelated 'off the shelf' allogeneic HLA-mismatched MSC products...
  29. ncbi request reprint Chronic graft-versus-host disease (cGVHD) following unrelated donor hematopoietic stem cell transplantation (HSCT): higher response rate in recipients of unrelated donor (URD) umbilical cord blood (UCB)
    Mukta Arora
    Blood and Marrow Transplant Program, Departments of Medicine and Pediatrics, University of Minnesota, Minneapolis, Minnesota 55455, USA
    Biol Blood Marrow Transplant 13:1145-52. 2007
    ..In addition, progressive onset of cGVHD was a significant predictor of increased mortality in URD cohort. These data suggest that cGVHD following UCB transplant may be more responsive to therapy and also lead to a lower NRM...
  30. pmc Allogeneic hematopoietic cell transplantation for hematologic malignancy: relative risks and benefits of double umbilical cord blood
    Claudio G Brunstein
    University of Minnesota Medical Center, Minneapolis, MN, USA
    Blood 116:4693-9. 2010
    ..For patients without an available HLA matched donor, the use of 2 partially HLA-matched UCB units is a suitable alternative...
  31. pmc Similar and promising outcomes in lymphoma patients treated with myeloablative or nonmyeloablative conditioning and allogeneic hematopoietic cell transplantation
    Marcie Tomblyn
    Blood and Marrow Transplant Program, Department of Medicine, University of Minnesota, Minneapolis, MN 55455, USA
    Biol Blood Marrow Transplant 14:538-45. 2008
    ..Modifications to refine patient assignment to the preferred conditioning intensity and reduce relapse risks with NMA approaches are needed...
  32. doi request reprint Does the hematopoietic cell transplantation specific comorbidity index predict transplant outcomes? A validation study in a large cohort of umbilical cord blood and matched related donor transplants
    Navneet S Majhail
    Blood and Marrow Transplant Program, University of Minnesota, Minneapolis, Minnesota 55455, USA
    Biol Blood Marrow Transplant 14:985-92. 2008
    ..The HCT-CI, although a useful tool for capturing pretransplant comorbidity and risk-assessment, needs to be further validated prior to adopting it for routine clinical use...
  33. ncbi request reprint Transplantation of unrelated donor umbilical cord blood in 102 patients with malignant and nonmalignant diseases: influence of CD34 cell dose and HLA disparity on treatment-related mortality and survival
    John E Wagner
    Blood and Marrow Transplant Program of the Department of Pediatrics, University of Minnesota Cancer Center and School of Medicine, Minneapolis 55455, USA
    Blood 100:1611-8. 2002
    ..7 x 10(5) CD34(+) cells per kilogram of recipient's body weight. Therefore, graft selection should be based principally on CD34 cell dose when multiple UCB units exist with an HLA disparity of 2 or less...
  34. pmc Acute graft-versus-host disease after unrelated donor umbilical cord blood transplantation: analysis of risk factors
    Margaret L Macmillan
    Blood and Marrow Transplant Program, University of Minnesota Medical School, Minneapolis, MN 55455, USA
    Blood 113:2410-5. 2009
    ..This study is registered at (http://www.clinicaltrials.gov) under the identifiers NCT00305682 and NCT00309842...
  35. ncbi request reprint Response of 443 patients to steroids as primary therapy for acute graft-versus-host disease: comparison of grading systems
    Margaret L Macmillan
    Department of Pediatrics, University of Minnesota, Minneapolis 55455, USA
    Biol Blood Marrow Transplant 8:387-94. 2002
    ..More effective prophylaxis and therapy for acute GVHD is needed for mismatched unrelated donor recipients and for those with severe GVHD...
  36. ncbi request reprint Searching for unrelated donor hematopoietic stem cells: availability and speed of umbilical cord blood versus bone marrow
    Juliet N Barker
    Department of Medicine, University of Minnesota School of Medicine, Minneapolis, USA
    Biol Blood Marrow Transplant 8:257-60. 2002
    ..These unique features of UCB transplantation must be considered in comparisons of the outcomes of UCB versus BM transplant recipients and in the design of prospective trials comparing URD sources...
  37. doi request reprint Hematopoietic cell transplantation for children with acute lymphoblastic leukemia in second complete remission: similar outcomes in recipients of unrelated marrow and umbilical cord blood versus marrow from HLA matched sibling donors
    Angela R Smith
    Division of Pediatric Hematology Oncology Blood and Marrow Transplantation, University of Minnesota Medical School, Minneapolis, Minnesota, USA
    Biol Blood Marrow Transplant 15:1086-93. 2009
    ....
  38. pmc Impact of cytomegalovirus (CMV) reactivation after umbilical cord blood transplantation
    Jill C Beck
    Department of Pediatrics, Division of Blood and Marrow Transplantation, University of Minnesota, Minneapolis, Minnesota 55455, USA
    Biol Blood Marrow Transplant 16:215-22. 2010
    ..01) and lower OS (P=.02). Thus, although recipient CMV serostatus and CMV reactivation have little demonstrable impact on UCB transplant outcomes, the development of CMV disease remains a risk, associated with inferior outcomes...
  39. pmc Umbilical cord blood transplantation after nonmyeloablative conditioning: impact on transplantation outcomes in 110 adults with hematologic disease
    Claudio G Brunstein
    Blood and Marrow Transplant Program, University of Minnesota, Minneapolis MN, USA
    Blood 110:3064-70. 2007
    ..01) and use of 2 UCB units (P = .07). These findings support the use of UCB after a nonmyeloablative conditioning as a strategy for extending the availability of transplantation therapy, particularly for older patients...
  40. ncbi request reprint Donor chimerism does not predict response to donor lymphocyte infusion for relapsed chronic myelogenous leukemia after allogeneic hematopoietic cell transplantation
    Elena G Chiorean
    Blood and Marrow Transplantation Program, University of Minnesota, Minneapolis 55455, USA
    Biol Blood Marrow Transplant 10:171-7. 2004
    ....
  41. ncbi request reprint High-producer interleukin-2 genotype increases risk for acute graft-versus-host disease after unrelated donor bone marrow transplantation
    Margaret L Macmillan
    Department of Pediatrics, University of Minnesota, MMC 484, 420 Delaware Street SE, Minneapolis, MN 55455, USA
    Transplantation 76:1758-62. 2003
    ..Because IL-2 is a proinflammatory cytokine, we hypothesized that recipients with high-producer genotypes would have increased frequency of GVHD after allogeneic bone marrow transplantation (BMT)...
  42. ncbi request reprint Transplantation of 2 partially HLA-matched umbilical cord blood units to enhance engraftment in adults with hematologic malignancy
    Juliet N Barker
    Blood and Marrow Transplant Program, Division of Medical and Pediatric Oncology, University of Minnesota, Box 480, 420 Delaware St SE, Minneapolis, MN 55455, USA
    Blood 105:1343-7. 2005
    ..Therefore, transplantation of 2 partially HLA-matched UCB units is safe, and may overcome the cell-dose barrier that limits the use of UCB in many adults and adolescents...
  43. ncbi request reprint Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer
    Jeffrey S Miller
    Division Medical and Pediatric Hematology Oncology, University of Minnesota Cancer Center, Minneapolis, MN 55455, USA
    Blood 105:3051-7. 2005
    ..These findings suggest that haploidentical NK cells can persist and expand in vivo and may have a role in the treatment of selected malignancies used alone or as an adjunct to HCT...
  44. ncbi request reprint Bronchiolitis obliterans in chronic graft-versus-host disease: analysis of risk factors and treatment outcomes
    Arkadiusz Z Dudek
    Bone Marrow Transplantation Program, University of Minnesota Health Sciences Center, 420 Delaware Street SE, MMC 480, Minneapolis, MN 55455, USA
    Biol Blood Marrow Transplant 9:657-66. 2003
    ..BrOb had high mortality rate of 55%, and pulmonary failure was the leading cause of death. More effective BrOb therapy is needed, especially for patients with unfavorable presentation...
  45. ncbi request reprint Serious infections after unrelated donor transplantation in 136 children: impact of stem cell source
    Juliet N Barker
    Division of Medical Hematology, Oncology, and Transplantation, University of Minnesota Blood and Marrow Transplant Program, Minneapolis, Minnesota, USA
    Biol Blood Marrow Transplant 11:362-70. 2005
    ..These data suggest that the risk of serious infection after pediatric UCB transplantation is comparable to that with unmanipulated BM...
  46. doi request reprint The best endpoint for acute GVHD treatment trials
    Margaret L Macmillan
    Blood and Marrow Transplant Program, University of Minnesota Medical School, 420 Delaware Street SE, Minneapolis, MN 55455, USA
    Blood 115:5412-7. 2010
    ..No other differences in response by donor source were observed. These data suggest that day 28 is the best early endpoint for acute GVHD therapeutic trials in predicting 2-year TRM...
  47. ncbi request reprint Interleukin-1 genotype and outcome of unrelated donor bone marrow transplantation
    Margaret L Macmillan
    Pediatrics Department, Blood and Marrow Transplant Program, University of Minnesota, Minneapolis, MN 55455, USA
    Br J Haematol 121:597-604. 2003
    ..2, P < 0.01) and decreased TRM (RR 0.1, P < 0.01). These data suggest that donor polymorphism in IL-1alpha and IL-1beta might influence survival after unrelated donor BMT, but does not alter risk of GVHD...
  48. ncbi request reprint Diffuse alveolar hemorrhage and infection-associated alveolar hemorrhage following hematopoietic stem cell transplantation: related and high-risk clinical syndromes
    Navneet S Majhail
    Blood and Marrow Transplant Program, Division of Hematology, Oncology and Transplantation, University of Minnesota, Minneapolis, MN 55455, USA
    Biol Blood Marrow Transplant 12:1038-46. 2006
    ..28). The pathogenesis of alveolar hemorrhage after HSCT is multifactorial, and we propose that IAH and DAH in HSCT recipients are related clinical syndromes with similar clinical presentation, risks, and associated high mortality...
  49. ncbi request reprint IL-2-based immunotherapy after autologous transplantation for lymphoma and breast cancer induces immune activation and cytokine release: a phase I/II trial
    L J Burns
    Blood and Marrow Transplant Program and Cancer Center, University of Minnesota, Mayo Mail Code 286, Minneapolis, MN 55455, USA
    Bone Marrow Transplant 32:177-86. 2003
    ..With this dose and schedule of administration of IL-2, no improvement in patient disease outcomes was noted. Alternative strategies will be needed to exploit the immunotherapeutic potential of IL-2-activated NK cells...
  50. doi request reprint Achieving stringent CR is essential before reduced-intensity conditioning allogeneic hematopoietic cell transplantation in AML
    C Ustun
    1 Division of Hematology, Oncology and Transplantation, Department of Medicine, University of Minnesota, Minneapolis, MN, USA 2 Blood and Marrow Transplant Program, University of Minnesota, Minneapolis, MN, USA
    Bone Marrow Transplant 48:1415-20. 2013
    ..A strict morphologic and clinical lab flow cytometric definition of CR predicts outcomes after RIC allo-HCT, and therefore is critical to achieve at transplantation. ..
  51. ncbi request reprint Autologous stem cell transplantation for high-risk Ewing's sarcoma and other pediatric solid tumors
    C J Fraser
    Department of Pediatrics, Division of Hematology, Oncology and Bone Marrow Transplantation, University of Minnesota, Minneapolis, MN 55455, USA
    Bone Marrow Transplant 37:175-81. 2006
    ..Median follow-up among survivors is 3.5 years (range: 0.6-7.9 years). These data justify continued investigation of ASCT as a consolidation therapy in patients with metastatic or relapsed ES and DSRCT...
  52. ncbi request reprint A prospective randomized trial of the anti-emetic efficacy of ondansetron and granisetron during bone marrow transplantation
    P J Orchard
    Program in Blood and Marrow Transplantation, Minneapolis, Minnesota, USA
    Biol Blood Marrow Transplant 5:386-93. 1999
    ..The relative cost of the drugs within an institution must be considered in developing standard anti-emetic regimens for bone marrow transplantation...
  53. ncbi request reprint Outcome of second hematopoietic cell transplantation in Hurler syndrome
    S S Grewal
    Pediatric Hematology Oncology, Blood and Marrow Transplantation, University of Minnesota, 420 Delaware Street SE, Minneapolis, MN 55455, USA
    Bone Marrow Transplant 29:491-6. 2002
    ..While graft failure in Hurler patients requires further investigation, a timely second HCT can be well-tolerated and beneficial...
  54. ncbi request reprint Fluconazole to prevent yeast infections in bone marrow transplantation patients: a randomized trial of high versus reduced dose, and determination of the value of maintenance therapy
    Margaret L Macmillan
    Department of Pediatrics, University of Minnesota, MMC 484, 420 Delaware Street Southeast, Minneapolis, MN 55455, USA
    Am J Med 112:369-79. 2002
    ..To determine the optimal dose and duration of fluconazole antifungal prophylaxis therapy in bone marrow transplantation patients...
  55. doi request reprint Determination of the minimum number of lymph nodes to examine to maximize survival in patients with esophageal carcinoma: data from the Surveillance Epidemiology and End Results database
    Shawn S Groth
    University of Minnesota Department of Surgery, Division of Thoracic Foregut Surgery, Minneapolis, MN 55455, USA
    J Thorac Cardiovasc Surg 139:612-20. 2010
    ..We used a population-based cancer registry to examine the association between lymph node counts and mortality to determine the minimum number of lymph nodes that should be examined as part of esophageal resection...
  56. ncbi request reprint GST genotype may modify clinical phenotype in patients with Fanconi anaemia
    Stella M Davies
    Cincinnati Children s Hospital Medical Center, Cincinnati, OH 45329, USA
    Br J Haematol 131:118-22. 2005
    ..GSTM1 genotype significantly influenced time to bone marrow failure in complementation group FA-C, (median age 3.0 years vs. 7.0 years, P < 0.01). GSTP1 genotype did not influence FA phenotype...
  57. ncbi request reprint Patient interleukin-18 GCG haplotype associates with improved survival and decreased transplant-related mortality after unrelated-donor bone marrow transplantation
    Sandra M P Cardoso
    Department of Pathology and Microbiology, University of Bristol, Homeopathic Hospital Site, Cotham, University Walk, Bristol BS8 1TD, UK
    Br J Haematol 126:704-10. 2004
    ..These data suggest that the IL-18 promoter GCG haplotype may influence survival after unrelated donor BMT without altering the risk of aGVHD...
  58. ncbi request reprint Interleukin-10 and tumor necrosis factor alpha region haplotypes predict transplant-related mortality after unrelated donor stem cell transplantation
    Leigh J Keen
    Molecular Immunogenetics Laboratory, Department of Pathology and Microbiology, University of Bristol, United Kingdom
    Blood 103:3599-602. 2004
    ..01. No independent associations of cytokine polymorphisms with acute graft-versus-host disease were shown...